INVITATION
We are proud to invite you to a very special event – the 10th Anniversary Meeting of the International Lipid Expert Panel (ILEP), taking place
on June 5–6, 2025, at the DoubleTree by Hilton in Warsaw.
The program will feature the latest scientific updates in lipidology, cardiology, and cardiovascular medicine, along with inspiring lectures by international experts and opportunities for experience sharing.
This year, in addition to the newest scientific findings and discussions on clinical guidelines, we will also celebrate the 15th anniversary of the Polish Lipid Association – one of the founding members of the Panel.
You can expect a rich scientific program, meetings with renowned experts, and plenty of opportunities to establish international collaborations.
Save the date and join us!
The founding member of the ILEP
Invited Faculty
PROGRAMME
10.00 – 11.00
Opening Plenary Session
Chairs: Prof. Maciej Banach, Prof. Zeljko Reiner
- 10 years of amazing collaboration within ILEP – what we achieved, what we are doing now, and what we plan to do?
Prof. Maciej Banach - Presentation and plans for the ILEP Sections’ Heads in Nutrition, Statistics, Pharmacy and Pharmacology and NEW Section of the Young Lipidologists and Preventionists
Prof. Arrigo F.G. Cicero, Prof. Ibadete Bytyçi, Dr Stanislaw Surma
11.00 – 12.00
Session on the Optimal Lifestyle Management 2025 – Discussion on the optimal and healthy diet.
Chairs: Prof. Arrigo F.G. Cicero, Dr Federica Fogacci, Prof. Dan Gaita
- What diets have the highest evidence for cardiovascular health? The optimal nutrition intervention 2025.
Prof. Anca Stoian - What diet for healthy subject, those with obesity and diabetes, and what diet for a patient after ACS? Personalization vs common approach for all.
Prof. Joanna Popiołek-Kalisz - International Lipid Expert Panel (ILEP) 2025 Position Paper on the recommendations on dietary management for the healthy heart + the ILEP Simple Healthy Tips
Prof. Arrigo F.G. Cicero - Discussion
12.00 – 12.15
Coffee break
12.15 – 13.15
Session on the Optimal Lifestyle Management 2025 – Discussion on the real role of nutraceuticals in every-day diet improvement.
Chairs: Prof. Atanas Atanasov, Prof. Jacek Jóźwiak, Prof. Joanna Popiołek-Kalisz
- Nutraceuticals with sufficient EBM data on efficacy and safety to recommend for selected patients with lipid disorders. ILEP recommendations.
Dr Federica Fogacci - Inflammation – the missing link between obesity, atherosclerosis, and HF. Any place for nonpharmacological approach?
Prof. Dragos Vinereanu - Diet and nutraceuticals might be not enough without good adherence both to diet and therapy.
Prof. Dan Gaita - Discussion
13.15 – 14.15
Session on the Optimal Lifestyle Management 2025 – Discussion on the role of regular exercises, smoking and stress to prevent cardiovascular and civilization diseases.
Chairs: Prof. Pierre Sabouret, Dr Anna Tylutka, Prof. Ibadete Bytyçi
- Regular exertion – the best ‘tablet’ to prevent CVD morbidity and mortality as well as all kind of civilization diseases? 2025 recommendations on the optimal physical exertion for the healthy heart.
Prof. Łukasz Małek - Different type of smoking and cardiovascular risk. Smoking cessation recommendations – it is possible to everybody!
Prof. Piotr Jankowski - Applications of X (formerly Twitter) in Healthcare Research and Practice
Prof. Atanas Atanasov - Discussion
14.15 – 15.00
Lunch
15.00 – 16.00
Session on the Lipid biomarkers 2025 – the association, causality, prediction, everything for optimal diagnosis and effective prevention.
Chairs: Prof. Bogdan Solnica, Prof. Gustavs Latkovskis, Prof. Peter P. Toth
- LDL-C, non-HDL or ApoB or maybe all three should be the main goal for monitoring, therapy and lipid disorders.
Prof. Peter P. Toth - TG, non-HDL, TRLs, sdLDL, and/or cholesterol remnants – the differences for diagnosis and suitable management. Role of EPA.
Prof. Niki Katsiki - Polish guidelines on diagnosis on lipid disorders – a step forward that all other should follow?
Dr Anna Tylutka - Discussion
16.00 – 17.00
Session on the Lipid biomarkers 2025 – lipoprotein(a) – the more we know, the less we know?
Chairs: Prof. Arman Postadzhiyan, Prof. Margus Viigimaa, Prof. Daniel Pella
- The current state of knowledge on the role of lipoprotein(a) in of cardiovascular disease risk. Association vs causality, in patients on LDL-C goal, at different age.
Prof. Zeljko Reiner - The role of Lp(a) in elderly. The ILEP 2025 recommendations on the lipid disorders management in the elderly patients.
Prof. Branislav Vohnout - Optimal hyper-Lp(a) management. Whether it is possible in 2025? The role of aspirin.
Prof. Daniel Pella - Discussion
17.00 – 17.15
Coffee break
17.15 – 18.15
Session on imaging techniques in lipid lowering management. Attempt at recommendations 2025
Chairs: Prof. Ronen Durst, Prof. Branislav Vohnout, Prof. Gustavs Latkovskis
- Primary and secondary prevention vs atherosclerosis prevention and lifetime CVD risk stratification. The role of CAC score and CCTA.
Prof. Michael D. Shapiro - Soft atheroma plaque, lipid core, total atheroma plaque, CAC power of zero – their predictiveness in the context of the early cardiovascular health investment.
Prof. Robert Gil - The role of imaging techniques in lipid lowering management and complications prevention – ILEP 2025 attempt at recommendations.
Prof. Pierre Sabouret - Discussion
18.15 – 19.30
Roundtable debate on the highest challenges in lipid disorders awareness, diagnosis and therapy. The best national-based cases to form the (CCE) European Plan for Prevention 2025.
Chair: Prof. Maciej Banach
Invited Experts:
-
- Prof. Dragos Vinereanu (Bucharest, Romania)
- Prof. Branislav Vohnout (Bratislava, Slovakia)
- Prof. Arman Postadzhiyan (Sofia, Bulgaria)
- Prof. Gani Bajraktari (Prishtina, Kosovo)
- Prof. Marek Gierlotka (Opole, Poland)
- Prof. Robert Gil (Warsaw, Poland)
- Prof. Gustavs Latkovskis (Riga, Latvia)
- Prof. Margus Viigimaa (Tallin, Estonia)
- Prof. Zlatko Fras (Ljubljana, Slovenia)
- Prof. Ivan Pećin (Zagreb, Croatia)
- Prof. Jacek Jóźwiak (Opole, Poland)
- Prof. Ibadete Bytyçi (Prishtina, Kosovo)
- Prof. Daniel Pella (Kosice, Slovakia)
- Prof. Anca Stoian (Bucharest, Romania)
10.00 – 11.00
Session on the lipid disorders management recommendations 2025. Part 1. Statins
Chairs: Prof. Peter E. Penson, Prof. Gani Bajraktari, Prof. Zlatko Fras
- Statins as a gold standard of lipid disorders therapy. When to start, how to treat effectively.
Prof. Arman Postadzhiyan - Whether all statins are the same? The focus on pitavastatin as a way for therapy personalization.
Dr Stanislaw Surma - Statin nonadherence, statin intolerance – the ILEP recommendations 2022 with the 2025 update.
Prof. Peter E. Penson - Discussion
11.00 – 12.00
Session on the lipid disorders management recommendations 2025. Part 2. Combination therapy
Chairs: Prof. Dragos Vinereanu, Prof. Zeljko Reiner, Prof. Marek Gierlotka
- Premature ASCVD – prevalence, risk factors, therapy and prevention. Whether combination LLT should be the first choice?
Prof. Ibadete Bytyçi - Combination therapy, preferably SPC/FDC, as the best way to be on the LDL-C target lower, earlier, with less adverse events and discontinuation. The lessons leant from hypertension therapy.
Prof. Margus Viigimaa - 2024 ILEP recommendations on the role of the upfront lipid lowering combination therapy in very high-risk CVD patients + PoLA recommendations on SPC.
Prof. Maciej Banach - Discussion
12.00 – 12.15
Coffee break
12.15 – 13.15
Session on the lipid disorders management recommendations 2025. Part 3. The place and availability of new therapies.
Chairs: Prof. Ivan Pećin, Prof. Tadeusz Osadnik, Prof. Zlatko Fras
- The recommendations on the role and place of bempedoic acid in lipid disorders patients.
Prof. Ivan Pećin - PCSK9 inhibitors and inclisiran. Who might benefit the most and what can be done to increase its availability for patients?
Prof. Marek Gierlotka - New therapies for severe hyperTG – focus on volanesorsen, olezarsen, pegozafermin, siRNA therapies.
Prof. Gustavs Latkovskis - Discussion
13.15 – 14.15
Session on the lipid disorders management recommendations 2025. Part 4. Hipertriglicerydemia and hyper-Lp(a)
Chairs: Prof. Peter P. Toth, Prof. Margus Viigimaa, Prof. Gustavs Latkovskis
- The current recommendations on the therapy of hyperTG and severe hyperTG (2025).
Prof. Peter P. Toth - The role of fenofibrate in the treatment of hypertriglicerydemia and microvascular complications. PoLA recommendations 2024.
Prof. Jacek Jóźwiak - Obicetrapib – the expected game changer in the therapy of dyslipidemia? What is new in this old group of CETP inhibitors.
Prof. Maciej Banach - Discussion
14.15 – 15.00
Lunch
15.00 – 16.00
Session on the lipid disorders management recommendations 2025. Part 5. Special populations
Chairs: Prof. Jacek Jóźwiak, Prof. Peter P. Penson, Prof. Pierre Sabouret
- The recent guidelines on the management with ACS extremely risk patients. How to effectively reduce and stabilize the atheroma plaque.
Prof. Zlatko Fras - Controversies around lipoprotein(a) – the role of apo(a) isoforms, proinflammatory and prothrombotic role, visit to visit variability, measurement.
Prof. Nathan D. Wong - The ILEP 2025 recommendations on the diagnosis and management of dyslipidemia during pregnancy.
Dr Joanna Lewek - Discussion
16.00 – 17.00
Session on the lipid disorders management recommendations 2025. Part 5. Special populations
Chairs: Dr Federica Fogacci, Prof. Agata Bielecka-Dabrowa, Prof. Zlatko Fras
- Dyslipidemia in patients with cancer. PTOK/PoLA 2025 recommendations.
Dr Bożena Sosnowska - How to diagnose and manage dyslipidemia in patients with liver diseases.
- Whether dyslipidemia may have any impact on heart failure?
Prof. Gani Bajraktari - Discussion
17.00 – 17.15
Coffee break
17.15 – 18.15
Session on the lipid disorders management recommendations 2025. Part 6. CVD Residual risk patients
Chairs: Prof. Agata Bielecka-Dąbrowa, Prof. Peter P. Penson, Prof. Dan Gaita
- Effective therapy for obesity and effective lipid lowering therapy – two brothers in arm?
Prof. Agata Bielecka-Dąbrowa - Recent recommendations on the management of atherogenic dyslipidemia in patients with diabetes.
Prof. Ronen Durst - Inflammation-related residual CVD risk. Prevalence, how to diagnose, how to prevent and treat. ILEP Recommendations 2025
Prof. Maciej Banach - Discussion
18.15 – 19.15
Session on the lipid disorders management recommendations 2025. Part 7. Management of patients with Familial Hypercholesterolemia
Chairs: Dr Joanna Lewek, Prof. Ibadete Bytyçi, Prof. Ronen Durst
- Simple tips on how to effectively genetically diagnose FH, especially those without confirmation of genetic diagnosis in the main genes.
Prof. Tadeusz Osadnik - The recent recommendations on FH diagnosis and therapy. The role of early diagnosis (universal screening) and combination therapy.
Prof. Ioanna Gouni-Berthold - What to do to improve diagnosis and therapy of FH in CEE countries. How to increase the number of patients treated with the innovative therapies?
Prof. Ivan Pećin - Discussion
19.15
Thanks and Closing Remarks
VENUE
DoubleTree by Hilton Hotel & Conference Centre
Skalnicowa 21, 04-797 Warszawa
PARTNERS
CONTACT
International Lipid Expert Panel (ILEP)
Rzgowska St. 281/289, 93-338 Lodz, POLAND
e-mail: patrycja.lewandowicz@ptlipid.pl
Copyright © 2025 – International Lipid Expert Panel (ILEP)